treatment modalities for such patients.
In this department, we provide treatment for head and neck malignancies with the intention of a permanent cure with preservation of organs and function. We report the treatment outcomes in five cases of maxillary cancer for which we utilized S-1 and nedaplatin with concurrent radiation therapy SN therapy from April 2005 to March 2009.
Patients and Methods
We administered SN therapy to five patients with maxillary cancer in this department from April 2005 to March 2009. With regard to histological type, all cases were identi ed as squamous cell carcinoma.
The research parameters were age, sex, follow-up duration, TNM Classification UICC Classi cation, 2002 , staging classi cation and treatment type.
The SN regimen used involved two courses, each consisting of a 14-day oral administration of S-1 80 mg / m 2 , an intravenous infusion of Nedaplatin 90 mg / m 2 on the fourth day and radiation therapy 1.2 Gy 2 / day for three weeks. The second course was initiated after a one-week break 1, 2 Fig. 1 . Radiation therapy consisted of a total of 69.6 Gy. SN therapy is indicated for patients younger than 80 years old with a creatinine clearance of more than 60 ml / minute and the absence of serious liver or cardiac disease. For patients over 75 years old the dosage is reduced to 70-80 of the normal dosage. Cisplatin, 5-FU and combination therapy with radiation are performed before SN therapy in our department. For renal function disorders cisplatin is replaced by nedaplatin.
The therapeutic protocol for maxillary cancer in this department is to administer radiation therapy after excision of the maxillary tumor in cases of T1 tumors. For T2 and T3 cases, SN therapy is provided after excision of the maxillary tumor. In T4 cases, one course of SN therapy is provided and excision of the maxillary tumor is performed two weeks later followed by the second course of SN therapy Fig. 2 .
All the operations involved a Denker s procedure.
Age / Sex
The patient ages ranged from 29 to 67 years and the average age was 55.6 years. The 
Follow-up Duration
The follow-up duration ranged from 15 months to 45 months and the average follow-up period was 32.4 months. The median value was 33 months.
TNM Classi cation / Staging Classi cation UICC Classi cation, 2002
Four cases were classi ed as T4NOMO Stage IV and one case as T2NOMO Stage II . 
Results
Treatment Details Table 1 The T2 case underwent an excision of the maxillary tumor followed by SN therapy. The observation period was 33 months and the patient is presently living without cancer. case 3 Fig. 3 . Sinus CT at rst examination A tumor progressing to the oral cavity and the right nasal cavity from the left maxillary sinus.
Fig. 4. Sinus CT after one course of SN therapy
The tumor is reduced. Four cases were classified as T4. These patients received one course of SN before undergoing an excision of the maxillary tumor. The second course of SN therapy was then administered. Three of these cases achieved a complete response CR . In one case, the administration of S-1 as an adjunctive chemotherapy was performed for two weeks followed by a two-week break. This pattern was performed for 12 months. The observation period was 31 months and the patient is presently living without cancer. case 1, Fig. 3, 4 , 5
In another case, UFT was administered as an adjunctive chemotherapy. After ten months a cervical lymph node metastasis appeared. This was surgically removed. The observation period was 45 months and the patient is presently living without cancer. case 2
Another of the T4 cases experienced a cervical lymph node metastasis after six months.
This tumor was also removed surgically. The observation period was 37 months and the patient is currently living without cancer. case 4
The remaining case did not achieve a CR. This patient received an arterial injection of docetaxel by the Seldinger method, followed by an arterial injection of 5FU from a super- In this department, we have achieved favorable outcomes 1 using SN therapy for cancer of the head and neck 2 . In cases of maxillary cancer, we preserve the palate and eyeball with a combination of SN therapy and partial resection of the maxilla. In four of the ve cases in this report, we were able to reduce the extent of surgery by administering SN therapy. Function and morphology could therefore be preserved. In the remaining case, however, an internal carotid invasion had already occurred at the time of diagnosis, and radical resection was impossible. Although we provided medical treatment according to departmental policy, the tumor persisted even after arterial injection chemotherapy. This patient developed a lung metastasis which we controlled locally with CyberKnife treatment.
This outcome demonstrates that CyberKnife treatment is a viable treatment option for cases of recurrence and PR.
Previous studies have reported ve-year survival rates for maxillary cancer patients ranging from 45.0 -62.5 , regardless of treatment variability 6 . For the preservation of the palate and eyeball however, outcomes vary between facilities and a rate of maxillary preservation of about 30.0 has been reported 3 . In this department, we administer SN therapy and perform partial resection of the maxilla. The palate is preserved via resection of the sidewall of the nasal cavity only. This treatment strategy maintains the QOL of patients by preserving function and morphology. However, it is dif cult to make comparisons with other reports with regard to the number of cases and follow-up duration. We hope to increase the number of patients in future studies to add weight to these results.
Conclusions
We reported the outcomes of SN therapy for ve cases of maxillary cancer. SN therapy allowed a reduction in the extent of surgery in order to preserve function and morphology.
To assess the effectiveness of this strategy, evaluation of the survival rates in addition to the effect preserving function and morphology is required. Towards this goal, we will study an increased number of such cases in the future.
